Reported 8 days ago
Jim Cramer recently highlighted Starbucks CEO Brian Niccol's efforts in revitalizing the brand, referring to him as a 'proven turnaround artist'. Despite Starbucks facing challenges, including layoffs and a slight reduction in store count, Cramer remains optimistic about the company's potential, especially in regards to its Chinese business, which is projected to be valued over $10 billion.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently advised against investing in Whirlpool Corporation (NYSE:WHR), particularly after the company cut its dividend, which he views as a negative signal for potential buyers. He compared the situation to the Cincinnati Bengals, emphasizing the company's struggling balance sheet and challenging market conditions. Despite Whirlpool's standing as a major U.S. appliance manufacturer, Cramer believes that there are better investment opportunities available, especially in the AI sector.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently discussed Salesforce, Inc. (NYSE:CRM) and its concerted effort to penetrate the enterprise sector using AI. Despite CEO Marc Benioff's keynote at Dreamforce unveiling the Agentforce initiative, the stock saw a decline, indicating Wall Street's skepticism about its immediate impact. Cramer noted the potential of CRM investments but mentioned that some AI stocks might present better upside with less risk.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently discussed Martin Marietta Materials, Inc. (NYSE:MLM), advising investors to hold their shares after a significant price increase. He emphasized that it's a strong long-term investment, similar to Vulcan Materials, and noted the company's benefit from ongoing federal infrastructure spending. While Cramer sees potential in MLM, he suggests that some AI stocks may offer better growth opportunities.
Source: YAHOO
Reported 8 days ago
Jim Cramer described Revolution Medicines, Inc. (NASDAQ:RVMD) as a 'speculative situation' during his lightning round segment, acknowledging its focus on developing therapies for RAS-driven cancers. He expressed a personal connection to cancer struggles and emphasized support for speculative stocks in the oncology field. Raymond James recently raised its price target for RVMD due to the promising acceptance of its treatment daraxonrasib into an FDA review process.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently commented on Verizon Communications Inc. (NYSE:VZ), describing it as akin to a bond with slight upward movement potential due to its strong cash flow and attractive 7% yield. He acknowledged improvements in the company's performance, noting that while it's not a top investment choice for him, it has become more favorable. Cramer believes there may be better investment opportunities in AI stocks with less risk.
Source: YAHOO
Reported 8 days ago
Jim Cramer has suggested that now is the right time to invest in Critical Metals Corp. (NASDAQ:CRML), which focuses on lithium and rare earth elements. He commented on a recent call that it would be beneficial for President Trump to acquire 10% of the company, though he doubts that will happen. The company recently secured $50 million in financing for its Tanbreez project in Greenland, which aims to meet the increasing demand for rare earths in the West.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently advised investors to consider reducing their stake in TopBuild Corp. (NYSE:BLD), citing that the stock price has surpassed its appropriate value despite his appreciation for the company. He noted that, although the firm has strong offerings in insulation and building materials, the overall market for these stocks has weakened.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently highlighted Okta, Inc. as a strong player in identity verification with excellent financial performance, despite the stock's decline of over 30% from its peak in May due to broader market skepticism toward enterprise software. He noted that Okta's numbers are impressive, but the market's lack of interest is puzzling. While expressing his preference for Okta, he suggested considering other companies in the identity management sector, such as Palo Alto Networks, for investment opportunities.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently analyzed Prologis, Inc.'s quarterly earnings, noting that despite a slowdown in parts of the commercial real estate sector, the company's strong report created an optimistic outlook that helped investors forget recent tough times. While he praised the company's leadership, Cramer expressed hesitance to invest in Prologis right now due to saturation in the warehouse market, suggesting he prefers other stocks.
Source: YAHOO
Reported 8 days ago
In a recent episode, Jim Cramer praised Lyft's significant stock rally of over 50% this year, suggesting it has more potential for growth. He expressed caution for investors wanting to buy at the current highs, advising them to wait for a pullback before investing further. While recognizing Lyft's potential, he also mentioned that certain AI stocks may offer even better returns with less risk.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently shared his thoughts on Intuitive Surgical, stating that despite acknowledging the company's potential, the stock is signaling not to buy. He noted that the competitive landscape has become challenging, and after a lackluster quarterly performance, he is hesitant to invest in ISRG. Cramer suggests that other AI stocks may currently offer better investment opportunities.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently shared his insights on Align Technology, suggesting that despite its low price-to-earnings ratio, the company faces significant challenges, including macroeconomic issues and changing consumer spending habits. Align, known for its Invisalign products, saw a dramatic drop in stock value after reporting disappointing numbers. Cramer emphasized that dental care generally should not be viewed as discretionary in the U.S., raising concerns about consumer priorities amid economic uncertainties.
Source: YAHOO
Reported 8 days ago
Jim Cramer recently discussed Kimberly-Clark Corporation, suggesting it might be nearing a bottom in its performance. He highlighted the company's current turnaround efforts under CEO Michael Hsu, while acknowledging that it is not considered a growth stock. Cramer also compared it to Procter & Gamble's recent improvements, but noted that other AI stocks might present better investment opportunities.
Source: YAHOO
Reported 8 days ago
Amazon, which started as an online bookstore in Washington 30 years ago, has grown to a market capitalization of over $2.3 trillion, dominating both e-commerce and cloud computing through its AWS division. With significant revenue streams and a focus on innovative technology, especially in artificial intelligence, Amazon is well-positioned for future growth, making it an attractive option for long-term investors considering its current lower stock price.
Source: YAHOO
Reported 8 days ago
Ondas Holdings Inc. (ONDS) has expanded its partnership with Rift Dynamics to include Nammo Raufoss, a leading munitions manufacturer in the U.S. Together, they will develop advanced Wasp Drones equipped with munition payloads, which will exclusively be marketed by Ondas's American Robotics subsidiary. This enhanced collaboration aims to create NDAA-compliant systems for rapid scale-up and deployment, marking a significant advancement for U.S. defense capabilities.
Source: YAHOO
Reported 8 days ago
Barclays has initiated coverage on ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a price target of $142. Analysts emphasize the promising risk/reward profile of investments in small and mid-cap biotechnology firms, particularly those with clinically backed data. Bharclays joins Guggenheim, which also has a Buy rating on ABIVAX with a target of $150. The company focuses on developing antiviral treatments and therapeutic vaccines for severe infectious diseases.
Source: YAHOO
Reported 8 days ago
Rigetti Computing (NASDAQ:RGTI) has recently gained over 20% in value following JP Morgan's announcement of a $1.5 trillion investment in critical industries, including quantum computing. The company secured $5.7 million in orders for two upgradeable quantum systems, expected to be delivered in early 2026. Market analysts are optimistic, with increased price targets reflecting confidence in Rigetti's potential.
Source: YAHOO
Reported 8 days ago
Navitas Semiconductor Corporation has announced the launch of new power semiconductor products specifically designed for Nvidia's 800 VDC AI factory architecture. These products include 100 V GaN FETs, 650 V GaN devices, and high-voltage SiC components, focused on improving efficiency and performance for high-capacity AI workloads. The new GaN FET portfolio aims to support Nvidia's shift to this advanced power distribution system, enhancing its infrastructure for AI capabilities.
Source: YAHOO
Reported 8 days ago
H.C. Wainwright has maintained a Buy rating on Stoke Therapeutics (NASDAQ:STOK), setting a price target of $35, due to the promising potential of its drug Zorevunersen for treating Dravet syndrome. Analyst Ananda Ghosh highlighted the positive long-term effects observed in the drug's trials, suggesting it could become the first disease-modifying therapy for the condition. Although STOK shows promise as an investment, it is suggested that some AI stocks may offer better potential returns.
Source: YAHOO
Reported 8 days ago
Roth Capital has raised the price target for D-Wave Quantum Inc. (NYSE:QBTS) from $20 to $50, maintaining a Buy rating. This increase follows the company's agreement to deploy a D-Wave Advantage2 quantum computer in Europe for 10 million euros. The deal is seen as a significant step towards potential hardware sales, reinforcing the constructive outlook on D-Wave Quantum.
Source: YAHOO
Reported 8 days ago
Susquehanna has raised its price target for SolarEdge Technologies (NASDAQ: SEDG) from $25 to $40, while keeping a Hold rating, citing strong confidence in the alternative energy sector due to favorable policies from the Inflation Reduction Act. Additionally, J.P. Morgan also adjusted their target for SEDG, increasing it from $27 to $29. Despite SEDG's potential, some analysts believe there are AI stocks with greater upside.
Source: YAHOO
Reported 8 days ago
Applied Digital Corporation (NASDAQ:APLD) has experienced a more than 25% increase in its stock price since its FQ1 2026 earnings release on October 9, where it reported a revenue of $64.22 million, surpassing expectations. Analysts from Lucid Capital and Needham have both issued Buy ratings, with price targets reaching up to $44 and $41, respectively, highlighting the company's strong position in the digital infrastructure sector, particularly in blockchain and AI technologies.
Source: YAHOO
Reported 8 days ago
Morgan Stanley has initiated coverage of Cidara Therapeutics, Inc. (NASDAQ:CDTX) with a Buy rating and a price target of $190, mainly due to its lead antiviral candidate, CD388, which is expected to play a significant role in the influenza prevention market. Analyst Maxwell Skor highlighted the potential of CD388, noting its single-dose prevention capability and upcoming important phase 3 results anticipated in June 2026. The drug's Fast Track and Breakthrough Therapy designations and a sizable addressable market further support the investment outlook.
Source: YAHOO
Reported 8 days ago
H.C. Wainwright has raised the price target for uniQure N.V. (QURE) from $70 to $110, maintaining a Buy rating due to positive results from the company's AMT-130 trials for Huntington’s disease. The stock has seen a remarkable increase of over 339% since the announcement, indicating the potential of AMT-130 to significantly alter the progression of the disease.
Source: YAHOO